Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement
Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
- Ricoh Company, Ltd. today announced a non-exclusive licensing agreement in the USA and Japan with ERS Genomics Limited ("ERS Genomics") for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS Genomics.
- In 2022, Ricoh completed the acquisition of Elixirgen Scientific, Inc. (Baltimore, Maryland, USA).
- Ricoh continues to contribute to the acceleration of drug development research through the diverse solutions provided by Elixirgen Scientific.
- Summit Pharmaceuticals International Corporation (Chiyoda-ku, Tokyo, Japan), a subsidiary of Sumitomo Corporation (Chiyoda-ku, Tokyo, Japan), is the exclusive representative of ERS Genomics in Japan.